Bladder Cancer Weekly

May 11, 2026

Videos

Peer-to-Peer Clinical Conversations

Moving Beyond TURBT: Durable LG-IR NMIBC Control with Primary Chemoablation - Sandip Prasad

Sandip Prasad

Zachary Klaassen is joined by Sandip Prasad to discuss long-term outcomes from the ENVISION trial evaluating mitomycin (ZUSDURI™) for low-grade intermediate-risk non-muscle invasive bladder cancer.

View

OPTIMA II Five-Year Data: Mitomycin Chemoablation Provides Durable Response in LG-IR-NMIBC - Neal Shore

Neal Shore

Neal Shore to discusses chemoablation with mitomycin (ZUSDURI™) for low-grade intermediate-risk non-muscle invasive bladder cancer.

View

Beyond the Abstracts

The Impact of Prophylactic Incisional Negative Pressure Wound Therapy on Surgical Site Infection Following Open Radical Cystectomy - Beyond the Abstract

The Effect of Chronic Liver Disease on Adverse In-Hospital Outcomes After Radical Cystectomy and Ileal Conduit Urinary Diversion - Beyond the Abstract

Conference Coverage

EAU 2026: Neoadjuvant and Adjuvant Enfortumab Vedotin + Pembrolizumab for Patients with Muscle Invasive Bladder Cancer Who Are Eligible for Cisplatin: Pathological and Surgical Outcomes in KEYNOTE-B15

EAU 2026: Phase 1 Study of B440, an Oral Bifidobacterium-Engineered WT1 Cancer Vaccine, in Patients with Metastatic Urothelial Cancer

EAU 2026: VI-RADS and PDD-TURBT to Avoid Second-look and Resection (Re-TURBT) in Non Muscle Invasive Bladder Cancers: The CUT-less Randomized Clinical Trial

ASCO GU 2026: – AGAINST: Bacillus Calmette-Guérin Plus Immune Checkpoint Inhibition for High-Risk Non-Muscle-Invasive Bladder Cancer

ASCO GU 2026: Enfortumab Vedotin and Pembrolizumab Outcomes in Patients with Advanced Urothelial Carcinoma and FGFR3 Alterations: UNITE Study Analysis

Articles

Editor Selected Abstracts and Commentaries

Bladder Cancer

Pathological assessment of morcellated tissue after ERBT: insights from a two-round Delphi survey.

Impact of European Association of Urology Combination and Platinum Eligibility on Real-World Treatment Sequences and Survival in Japanese Patients With Metastatic Urothelial Carcinoma.

Preoperative FAN score predicts survival outcomes after radical cystectomy for bladder cancer.

The Antipsychotic Aripiprazole Induces Cytotoxicity in Bladder Cancer Cells While Preserving Urothelial and Bladder Function.

Clinical performance of the urine-based TERT promoter AbsoluteQ Digital PCR for non-invasive detection of bladder cancer.

Digital PCR-Based Uromonitor for Molecular Detection of Bladder Cancer: A Multicenter Validation Study Comparing Quantitative PCR and Urine Cytology - Beyond the Abstract

A systematic review and meta-analysis of clinicopathologic factors associated with adverse oncologic outcomes in bladder cancer patients undergoing radical cystectomy: Evidence from multivariable survival prediction models.

Factors influencing adherence to intravesical instillation therapies for non-muscle-invasive bladder cancer: a scoping review protocol.

Divergent Macrophage-Regulated T cell States Determine Response to Bacillus Calmette-Guérin vaccine in High-Risk Bladder Cancer.

Assessing the Relationship Between Bladder Cancer cell Contractile Phenotypes and their Invasive Properties.

New Health Economic Methodology Published: Comparing Cost-Effectiveness of BLC Versus NBI Imaging Technology in Bladder Cancer

Clinical value of VI-RADS score in predicting repeat transurethral resection in primary bladder cancer: a prospective observational study.

Addressing the challenges of health economic modelling in the context of suboptimal evidence base – case study based on a comparison between photodynamic diagnosis and narrow band imaging in non-muscle invasive bladder cancer

Urinary Extracellular Vesicles for High-Precision Bladder Cancer Subtyping and Prognosis.

Preferred Treatment Sequencing for Metastatic Urothelial Carcinoma (mUC) in the Era of Perioperative and First-Line (1L) Checkpoint Inhibitor: Results From a National Survey of Genitourinary Oncologists - Beyond the Abstract

CONNECT WITH US

Questions or Comments? Email us at editors@urotoday.com

Digital Science Press, LLC
2011 Phaethon Lane,
Reno, NV 89523

You are receiving this email because you have chosen to receive emails from UroToday.

Bladder Cancer Weekly

Bladder Cancer

Login